Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing topical and systemic treatments for immune-mediated dermatological diseases. The company's lead product, ZORYVE, is a phosphodiesterase-4 (PDE4) inhibitor available in cream and foam formulations for the treatment of plaque psoriasis, seborrheic dermatitis, and atopic dermatitis. ZORYVE cream is approved for plaque psoriasis in individuals aged six and older, while ZORYVE foam treats seborrheic dermatitis and plaque psoriasis of the scalp and body. Additional ZORYVE cream formulations are indicated for mild to moderate atopic dermatitis in adults and pediatric patients. The company also holds ARQ-234, a CD200 Receptor agonist in development for atopic dermatitis and other inflammatory conditions. Arcutis serves markets in the United States and Canada, with licensing agreements in place for Greater China, Southeast Asia, and Japan. The company was founded in 2016 and acquired Ducentis BioTherapeutics in 2022 to expand its pipeline.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage arcutis.com
Sector Healthcare IR page investors.arcutis.com
Tags
dermatology, topical treatments, psoriasis, atopic dermatitis, seborrheic dermatitis, pde4 inhibitors, roflumilast, immune-mediated diseases, biologics, cd200r agonists, ZORYVE, ZORYVE cream, ZORYVE foam, ARQ-234, Ducentis BioTherapeutics, DS-234
Press page arcutis.com/news-media

Metrics

Valuation  
Market cap $ 3.549B
Market cap (USD) $ 3.549B
P/E 128.00
PEG —
P/BV 14.55
P/S 7.00
P/OCF 59.18
P/FCF 59.44
Dividend yield —
Turnover / mcap —
Returns  
ROE -9.3%
ROI -5.4%
ROIC -3.1%
Profit margin -4.3%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 44.8%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 72
Quality score -11.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 372.072M 166.542M 59.606M 3.686M — — —
Net profit -16.141M -140.039M -262.14M -311.458M -206.356M -135.678M -41.996M
Free cash flow -6.311M -112.301M -247.485M -258.048M -175.622M -113.354M -43.131M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 29.04 13.93 3.23 14.8 20.74 28.13 —
Price performance 12m 1.08 3.31 -0.78 -0.29 -0.26 — —

Filed figures

Figure Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — 0.00 8.46M 25.8M 73.1M 146M
↳ YoY growth +205.1% +183.1% +100.1%
Borrowings, current (USD) — — — — — — 0.00 0.00 1M
Borrowings, non-current (USD) — — — 0.00 72.4M 198M 202M 107M 108M
Lease liabilities (USD) — — 307,000 4.96M 5.21M 4.77M 4.12M 3.38M 5.56M
Cash and deposits (USD) 3.42M 39.4M 63.3M 65.1M 96.4M 53.6M 88.4M 71.3M 42.9M
Intangible assets (USD) — — — — 0.00 7.19M 6.44M 9.48M 14.8M
Right-of-use assets (USD) — — 264,000 3.35M 3.04M 2.72M 2.36M 1.95M 4.47M
Net debt (borrowings + leases - cash) (USD) — — — -60.1M -18.9M 149M 118M 39.3M 71.6M
Cash flow detail
Operating cash flow (USD) — -14.1M -42.8M -113M -175M -258M -247M -112M -5.63M
Purchases of property, plant and equipment (USD) — 0.00 -295,000 -321,000 -995,000 -333,000 -428,000 -143,000 -686,000
Purchases of intangible assets (USD) — — — — 0.00 -7.5M 0.00 -5M -10M
Change in receivables (cash effect) (USD) — — — 0.00 0.00 -8.46M -17.3M -47.3M -73.2M
Change in inventories (cash effect) (USD) — — — 0.00 0.00 -7.51M -5.62M -400,000 -7.33M
Change in payables (cash effect) (USD) — 1.26M -458,000 5.67M 245,000 1.57M 3.15M 2.23M -1.69M
Interest paid (cash effect) (USD) — — 0.00 0.00 -142,000 -12.6M -25.4M -22.2M -10.3M
Income taxes paid (cash effect) (USD) — — — — — — 0.00 0.00 0.00
Share-based compensation (USD) — 151,000 824,000 7.94M 23.9M 32.7M 38.8M 41.7M 40.4M
Operating cash flow before change in receivables (USD) — — — -113M -175M -249M -230M -64.9M 67.5M
Free cash flow (OCF - PPE - intangibles) (USD) — -14.1M -43.1M -113M -176M -266M -247M -117M -16.3M
Income detail
Research and development expense (USD) — 17.9M 36.5M 115M 146M 182M 111M 76.4M 77.1M
↳ 5y CAGR +43.9% +15.9% -7.7%
Total comprehensive income (USD) — -19.3M -42M -136M -207M -312M -261M -140M -16.2M
Comprehensive income to owners (USD) — -19.3M -42M -136M -207M -312M -261M -140M -16.2M
Reported Feb 16, 2021 Feb 16, 2021 Feb 22, 2022 Feb 28, 2023 Feb 28, 2023 Feb 25, 2025 Feb 25, 2026 Feb 25, 2026 Feb 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

News & Media

Press Releases

Back to News & Media

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PDF Version


WESTLAKE VILLAGE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 58,500 restricted stock units (RSUs) of Arcutis common stock as well as options to purchase an aggregate of 17,000 shares of Arcutis’ common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of November 2, 2026, as a material inducement to the new employees in connection with their commencement of employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest over four years, with 25 percent vesting on each annual anniversary of the vesting commencement date, subject to each employee’s continued employment with Arcutis through the applicable vesting date. The stock options will vest over four years, with 25 percent vesting on the one-year anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Arcutis as of such vesting dates. The stock options have a ten-year term and an exercise price of $31.26 per share, equal to the per share closing price of Arcutis’ common stock as reported by Nasdaq on November 2, 2026.

Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Arcutis

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company delivering meaningful innovation to address the needs of individuals living with chronic inflammatory skin diseases. Over the past decade, Arcutis has successfully developed a robust portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases, driven by a commitment to solving the most persistent patient challenges in dermatology. Arcutis’ unique dermatology development platform, built on established scientific pathways and coupled with deep clinical dermatology and commercial expertise, enables us to efficiently develop, scale, and deliver our differentiated therapies while advancing a growing pipeline across a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com  or follow Arcutis on LinkedIn , Facebook , Instagram , and X .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations and are subject to substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Skip to content

News Release Details

Back to News

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 6, 2026 at 4:00 PM EST

PDF Version

WESTLAKE VILLAGE, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 58,500 restricted stock units (RSUs) of Arcutis common stock as well as options to purchase an aggregate of 17,000 shares of Arcutis’ common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of November 2, 2026, as a material inducement to the new employees in connection with their commencement of employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest over four years, with 25 percent vesting on each annual anniversary of the vesting commencement date, subject to each employee’s continued employment with Arcutis through the applicable vesting date. The stock options will vest over four years, with 25 percent vesting on the one-year anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Arcutis as of such vesting dates. The stock options have a ten-year term and an exercise price of $31.26 per share, equal to the per share closing price of Arcutis’ common stock as reported by Nasdaq on November 2, 2026.

Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Arcutis

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company delivering meaningful innovation to address the needs of individuals living with chronic inflammatory skin diseases. Over the past decade, Arcutis has successfully developed a robust portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases, driven by a commitment to solving the most persistent patient challenges in dermatology. Arcutis’ unique dermatology development platform, built on established scientific pathways and coupled with deep clinical dermatology and commercial expertise, enables us to efficiently develop, scale, and deliver our differentiated therapies while advancing a growing pipeline across a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations and are subject to substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

November 5, 2026 at 8:00 AM EST

PDF Version

  • New INTEGUMENT-3 study to evaluate efficacy, safety, and tolerability of investigational ZORYVE® cream 0.3% in individuals with moderate to severe atopic dermatitis

  • Study aims to expand once-daily ZORYVE cream treatment to individuals with moderate to severe atopic dermatitis

  • Builds on existing evidence of ZORYVE cream 0.15% for individuals ages 6 and older and ZORYVE cream 0.05% for children ages 2 to 5 with mild to moderate atopic dermatitis

WESTLAKE VILLAGE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the first participant has been enrolled in a Phase 3, double-blind, randomized, vehicle-controlled study, INTEGUMENT-3. The study is designed to evaluate the efficacy, safety, and tolerability of once-daily ZORYVE® (roflumilast) cream 0.3% for the treatment of individuals ages 6 and older with moderate to severe atopic dermatitis.

“ZORYVE cream has an established efficacy and safety profile in mild to moderate atopic dermatitis, and we see an opportunity to bring the benefits of this innovative treatment to more people living with the disease by evaluating the higher concentration of ZORYVE cream 0.3% in individuals with more severe atopic dermatitis,” said Patrick Burnett, MD, PhD, FAAD, chief medical officer at Arcutis. “Despite advances in treatment, many people with moderate to severe atopic dermatitis continue to experience significant disease burden and are in need of additional treatment options. The initiation of INTEGUMENT-3 marks an important step towards expanding the indication of ZORYVE to fill this gap.”

About INTEGUMENT-3 INTEGUMENT-3 (ARQ-151-323) is a Phase 3, multicenter, randomized, double-blind, vehicle-controlled study evaluating the efficacy, safety, and tolerability of once-daily ZORYVE cream 0.3% in children, adolescents, and adults 6 years of age and older with moderate to severe atopic dermatitis.

Approximately 415 participants aged 6 years and older with moderate to severe atopic dermatitis (validated Investigator Global Assessment for Atopic Dermatitis [vIGA-AD] score of 3 or 4, EASI ≥5, and BSA 3%-30%) will be randomized in a 2:1 ratio to receive either ZORYVE cream 0.3% or matching vehicle cream once daily for 4 weeks during the double-blind treatment period. The primary objective of the study is to assess the safety and efficacy of ZORYVE cream 0.3% compared with vehicle cream administered once daily for 4 weeks in participants aged 6 years and older with moderate to severe atopic dermatitis. A secondary objective is to assess the long-term safety and efficacy of ZORYVE cream 0.3% administered once daily for up to 52 weeks in this patient population.

Participants who complete the double-blind treatment period will be eligible to enter a 48-week open-label extension period, during which all participants will receive once-daily ZORYVE cream 0.3%. The open-label extension is designed to evaluate the long-term safety, tolerability, and efficacy of ZORYVE cream 0.3% up to 52 weeks.

About Atopic Dermatitis Atopic dermatitis is the most common type of eczema, affecting approximately 9.6 million children and 16.5 million adults in the United States. Atopic dermatitis is a chronic, relapsing, and genetically predisposed inflammatory skin disease. The disease typically appears as a red, intensely itchy rash that can occur anywhere on the body. Younger children may have especially widespread atopic dermatitis, including on the face and neck.

Atopic dermatitis is often initially diagnosed during childhood with approximately 90% of people with atopic dermatitis developing symptoms by age 5 and up to 60% of children developing symptoms within their first year. Pediatric atopic dermatitis can negatively impact the entire family by significantly disrupting sleep, increasing the risk of skin infections, and leading to developmental and emotional strain for both the child and caregivers.

Atopic dermatitis is often characterized as mild to moderate and moderate to severe. Severe eczema can come with additional complications beyond itchy skin and rashes, such as infections that can lead to hospitalization if left untreated.

**About ZORYVE® (roflumilast)**ZORYVE is the number one prescribed branded topical therapy across three major inflammatory dermatoses combined — atopic dermatitis (eczema), seborrheic dermatitis, and plaque psoriasis. ZORYVE is a topical formulation of roflumilast, an advanced targeted topical phosphodiesterase type 4 (PDE4) inhibitor. Inhibiting PDE4, an intracellular enzyme that is an established target in dermatology, decreases the production of pro-inflammatory mediators. This decreases inflammation in the skin and balances the skin’s immune system.

Demonstrating both clinical impact and broad industry recognition, ZORYVE has been honored with multiple prestigious awards, including three from major beauty magazines: Allure’s "2025 Best of Beauty Breakthrough Award," Glamour’s 2024 Beauty and Wellness Award for “Best Eczema Product,” and most recently, Marie Claire’s “2026 Best Prescription Skin Solution” Award.

In addition, the National Psoriasis Foundation honored ZORYVE with its Seal of Recognition and the American Academy of Dermatology (AAD) issued a strong recommendation for the use of ZORYVE cream 0.15% in adults with mild to moderate atopic dermatitis and ZORYVE cream 0.05% for children aged 2-5 years, as well as a strong recommendation for ZORYVE cream 0.15% for children aged 6 years and older with mild to moderate atopic dermatitis in its first-ever pediatric atopic dermatitis guidelines.

INDICATIONS ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age.

ZORYVE cream, 0.15%, is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older.

ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older.

ZORYVE topical foam, 0.3%, is indicated for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older.

ZORYVE topical foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.

IMPORTANT SAFETY INFORMATION ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).

Flammability: The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application.

The most common adverse reactions reported (≥1%) for ZORYVE cream 0.05% for pediatric patients with atopic dermatitis 2 to 5 years of age were upper respiratory tract infection (4.1%), diarrhea (2.5%), vomiting (2.1%), rhinitis (1.6%), conjunctivitis (1.4%), and headache (1.1%).

The most common adverse reactions reported (≥1%) for ZORYVE cream 0.15% for patients with atopic dermatitis 6 years of age or older were headache (2.9%), nausea (1.9%), application site pain (1.5%), diarrhea (1.5%), and vomiting (1.5%).

The most common adverse reactions reported (≥1%) for ZORYVE cream 0.3% for plaque psoriasis were diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%).

The most common adverse reactions reported (≥1%) for ZORYVE foam 0.3% for plaque psoriasis were headache (3.1%), diarrhea (2.5%), nausea (1.7%), and nasopharyngitis (1.3%).

The most common adverse reactions reported (≥1%) for ZORYVE foam 0.3% for seborrheic dermatitis were nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).

Please see full Prescribing Information for ZORYVE foam and full Prescribing Information for ZORYVE cream.

About Arcutis Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company delivering meaningful innovation to address the needs of individuals living with chronic inflammatory skin diseases. Over the past decade, Arcutis has successfully developed a robust portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases, driven by a commitment to solving the most persistent patient challenges in dermatology. Arcutis’ unique dermatology development platform, built on established scientific pathways and coupled with deep clinical dermatology and commercial expertise, enables us to efficiently develop, scale, and deliver our differentiated therapies while advancing a growing pipeline across a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the potential of ZORYVE cream 0.3% to advance the standard of care in atopic dermatitis. These statements are subject to substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Prompts

Arcutis Biotherapeutics, Inc. (ticker ARQT), listed in United States.

Company History

Date Change Detail
Oct 7, 2019 Renamed Arcutis, Inc. → ARCUTIS BIOTHERAPEUTICS, INC.

ETFs Holding Arcutis Biotherapeutics, Inc.

ETF Weight in ETF Shares Market value As of
PINK 8.80% 1,077,695 $ 29.453M Nov 17, 2026
AFSC 2.14% 7,995 $ 214.746K Jul 31, 2026
FSCC 0.61% 92,988 $ 2.229M Aug 31, 2026
HELX 0.42% 4,422 $ 115.945K Jun 30, 2026
AFSM 0.20% 10,747 $ 291.781K Nov 16, 2026
FSEG 0.20% 432 $ 11.327K Jun 30, 2026
PSC 0.19% 172,935 $ 4.534M Jun 30, 2026
SEIS 0.18% 40,041 $ 1.05M Jun 30, 2026
MMSC 0.15% 2,747 $ 74.581K Nov 16, 2026
FESM 0.12% 258,057 $ 6.766M Jun 30, 2026
FSML 0.10% 4,946 $ 129.684K Jun 30, 2026
RESM 0.09% 129 $ 3,382.38 Jun 30, 2026
VFMO 0.02% 19,935 $ 477.842K Aug 31, 2026
MSSM 0.01% 4,172 $ 100.003K Aug 31, 2026
DXUV 0.01% 24,443 $ 672.916K Nov 12, 2026
DFAS 0.00% 49,909 $ 1.374M Nov 12, 2026
DFUS 0.00% 14,191 $ 390.678K Nov 12, 2026
DCOR 0.00% 26,027 $ 716.523K Nov 12, 2026
DFAC 0.00% 34,547 $ 951.079K Nov 12, 2026
DFAU 0.00% 1,936 $ 53.298K Nov 12, 2026